OneOme is working to deliver the highest quality, most cost-effective pharmacogenomic testing and tools for all providers across the globe to use in everyday patient care. By increasing adoption of pharmacogenomics, OneOme and the RightMed Test may help providers make more informed medication decisions, with the aim of decreasing medication trial and error and reducing healthcare costs.
As a leader in the pharmacogenetics (PGx) space, OneOme believes this is a positive step toward achieving consensus evidentiary standards for PGx...
CLEVELAND and MINNEAPOLIS, Dec. 2, 2019 /PRNewswire/ -- Family Care Path, Inc. a health technology company that brings applications benefiting people to the healthcare market, today announced a new partnership with Minneapolis-based pharmacogenomic (PGx) solutions company, OneOme, LLC. Through this...
MINNEAPOLIS and 'S-HERTOGENBOSCH, Netherlands, Nov. 19, 2019 /PRNewswire/ -- OneOme today announced a pilot partnership with Alliance Healthcare Netherlands (a wholly owned subsidiary of Walgreens Boots Alliance) that will bring pharmacogenomic testing to selected Boots and Alphega Pharmacy location...
MINNEAPOLIS – July 8, 2019 – OneOme has named Patrick McIntyre, a healthcare executive with more than three decades of experience in management, operations, and finance, as its Chief Executive Officer. McIntyre replaces Paul Owen, who joined to lead the company in 2015 and who will oversee the t...
People of OneOme
PATRICK MCINTYRE — CHIEF EXECUTIVE OFFICER
Patrick joined OneOme as Chief Executive Officer in July 2019. Patrick has more than 25 years of healthcare experience, the vast majority of which has been in leadership roles over advanced analytics, healthcare economics, clinical informatics, and medical finance in national and regional payer organizations. He has built and led industry-leading analytics capabilities at UnitedHealthcare/Optum, Anthem, and Aetna. Patrick received his MBA from Winthrop University and his BBA from Texas Tech University. He is a former Certified Public Accountant in South Carolina, and he served for 5 years on active duty in the United States Marine Corps.
BRONWYN HARTUNG, PHD, HCLD(ABB) — LABORATORY DIRECTOR
Bronwyn is the founder of Phoenix Laboratory Consulting, based in Prospect, Kentucky. She has 15 years of experience in molecular genetics, with expertise in the design and validation of laboratory-developed tests, high-complexity clinical laboratory operations, quality systems, regulatory compliance, and medical device software. Bronwyn is a contributing member of CPIC, PharmVar, and the FDA PGx Collaborative Community, and she is on the steering committee of the STRIPE Initiative. She earned her B.S. in Biology at Trinity University and her Ph.D. at Indiana University, followed by a postdoctoral fellowship in microbial pathology at the University of Iowa.
COLIN SCHULTE — SENIOR DIRECTOR OF FINANCE
Colin joined OneOme as a Senior Finance Director in December 2019. He is a Certified Healthcare Financial Professional (CHFP), experienced in financial reporting, budgeting, modeling, and accounting. His technical finance and accounting experience is paralleled by industry knowledge, system expertise, and collaboration skills. Previously, he held roles leading financial analytics for the University of Minnesota Physicians and managing finance and accounting at Gravie, a venture-backed health insurance brokerage. Colin received his BA from Hamline University and is currently completing his MBA at Saint Mary’s University of Minnesota.
JONATHAN YOUNT — GROWTH OFFICER
Jonathan joined OneOme as Growth Officer in 2019. He has an extensive background of over 15 years of experience in both the personalized medicine and the pharmaceutical industries. He brings a strong history of both diverse leadership and strategic skills. He has successfully demonstrated that he excels at building sales teams and leading them to exceeding objectives and goals. Jonathan has a B.S. degree from Texas Christian University and a M.S. degree from Purdue University.
JULIE ENGLAND, MD — Interim Chief Medical Officer
Dr. Julie England joined OneOme in September 2018. She is a board-certified physician with over 15 years of clinical experience in Family Medicine, which has allowed her to encounter a variety of medical issues. While performing in this setting, she became interested in precision medicine and eventually opened up a small concierge lifestyle precision medicine practice in 2017. Julie received her B.A. in Biology from the University of Michigan and her M.D. from the American University of the Caribbean College of Medicine. She completed her residency training in Family Medicine at the University of Minnesota.
TANYA RYLEE — Chief Administrative Officer
Prior to joining OneOme, Tanya worked at Anthem, Inc. for almost six years in executive roles focused on strategy, planning, and process improvement. Previously, she was employed by UnitedHealth Group for 11 years, where she worked within the areas of program and project management and served as chief of staff for Quality Management and Performance. In 2016, she was honored as one of the 51 Women in Business award winners by the Minneapolis/St. Paul Business Journal. Tanya holds a B.S. in Dietetics and a minor in Psychology from the University of North Dakota and a M.B.A. degree from Webster University.
JOHN L. BLACK III, M.D. — MAYO CLINIC, CO-FOUNDER ONEOME
John L. Black III, M.D. is one of the co-founders of OneOme and also a consultant in the Division of Clinical Biochemistry and Immunology with a joint appointment in the Department of Psychiatry and Psychology at Mayo Clinic in Rochester. He joined the staff of Mayo Clinic in 1985 and is currently the co-director of the Personalized Genomics Laboratory. He received his B.A. and M.S. in psychology from the University of Wyoming. He received his M.D. (cum laude) from Creighton University School of Medicine. He is board certified in general, geriatric, and addiction psychiatry and is a clinical chemist.
LIEWEI WANG, M.D., Ph.D. — MAYO CLINIC, Co-founder OneOme
Dr. Wang is a professor in the Department of Molecular Pharmacology and Experimental Therapeutics (MPET) at Mayo Clinic Rochester. Her research involves the application of high-throughput "omics" technologies to identify biomarkers that might help us individualize cancer therapies, understand mechanisms of drug action, and facilitate target identification and drug development. She is also a co-leader of the Mayo Pharmacogenomics Program within the Mayo CIM, where many of the projects involving personalized medicine have been conducted. She is the co-PI for the Mayo-NIH clinical pharmacology T32 training grant and the Associate Director for the Mayo MPET graduate program.
RICHARD WEINSHILBOUM, M.D. — MAYO CLINIC, Co-founder OneOme
Dr. Weinshilboum received B.A. and M.D. degrees from the University of Kansas, followed by residency training in internal medicine at the Massachusetts General Hospital. He was also a pharmacology Research Associate at the National Institutes of Health (NIH). He began his affiliation with the Mayo Medical School and Mayo Clinic in 1972, where he is presently Professor of Pharmacology and Medicine and Mary Lou and John H. Dasburg Professor of Cancer Genomics Research. He currently directs the Pharmacogenomics Program of the Mayo Center for Individualized Medicine and is co-Principal Investigator of the long-standing US NIH Pharmacogenomics Research Network Center at the Mayo Clinic.
Esquivel, MD, MHA, PhD
Elnashar, PharmD, MS
Soundararajan, PharmD (Intl.), MS
- The RightMed Test must be ordered by a physician.
- The RightMed Test, as with all genomic testing, has limitations. Always discuss the test with a healthcare provider knowledgeable about the test and to see if it's right for you.
- RightMed Test results are not a substitute for medical advice and should only be used in consultation with a medical professional.
- The RightMed Test does not determine the best medication for the patient; it is a tool to provide additional information to the patient’s healthcare provider. The healthcare provider should take other factors into consideration regardless of genotype.
- Independent healthcare providers available through OneOme's service will not have all of your health history, which may cause the test results to be subject to a different interpretation than by your personal physician.
- DO NOT MAKE ANY CHANGES TO YOUR CURRENT MEDICATIONS OR DOSING WITHOUT CONSULTING YOUR HEALTHCARE PROVIDER.